

# David F Mcdermott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676663/publications.pdf>

Version: 2024-02-01

357  
papers

74,445  
citations

7069

78  
h-index

547

264  
g-index

366  
all docs

366  
docs citations

366  
times ranked

50952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. <i>Melanoma Research</i> , 2022, 32, 35-44.	0.6	2
2	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
3	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
4	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
5	Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 362-362.	0.8	3
6	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
7	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
8	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
9	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
10	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
11	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
12	Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2500-2500.	0.8	17
13	Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4557-4557.	0.8	2
14	A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4599-TPS4599.	0.8	4
15	A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4511-4511.	0.8	7
16	Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4544-4544.	0.8	2
17	Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4509-4509.	0.8	11
18	Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4538-4538.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. Journal of Clinical Oncology, 2022, 40, e16521-e16521.	0.8	0
20	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	3.2	12
21	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	0.9	64
22	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research, 2021, 9, 156-169.	1.6	56
23	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. Radiology, 2021, 298, 332-340.	3.6	13
24	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
25	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154
26	A phase 1b trial of the CXCR4 inhibitor mavoxixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs, 2021, 39, 1019-1027.	1.2	22
27	TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.. Journal of Clinical Oncology, 2021, 39, 278-278.	0.8	2
28	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	5.8	84
29	The oral HIF-2 $\alpha$ inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.. Journal of Clinical Oncology, 2021, 39, 273-273.	0.8	19
30	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-“Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1029-1039.	0.8	145
31	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European Journal of Cancer, 2021, 145, 1-10.	1.3	17
32	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1020-1028.	0.8	83
33	Inhibition of hypoxia-inducible factor-2 $\alpha$ in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Medicine, 2021, 27, 802-805.	15.2	151
34	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	0.8	5
35	TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2021, 39, 4546-4546.	0.8	2
36	TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.. Journal of Clinical Oncology, 2021, 39, e16553-e16553.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.. Journal of Clinical Oncology, 2021, 39, 9522-9522.	0.8	1
38	Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.. Journal of Clinical Oncology, 2021, 39, 4567-4567.	0.8	1
39	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	0.9	20
40	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230
41	Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). Cancer Research, 2021, 81, CT188-CT188.	0.4	3
42	First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis. Kidney Cancer, 2021, 5, 153-163.	0.2	1
43	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer, 2021, 19, 468.e1-468.e5.	0.9	7
44	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 434-446.	0.9	16
45	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	3.2	25
46	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
47	424â€¦A phase 1b/2 randomized study of AVB-S6â€“500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment. , 2021, 9, A454-A454.		2
48	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
49	349â€¦Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3. , 2021, 9, A376-A376.		1
50	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	0.8	109
51	Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 179-184.e3.	0.9	6
52	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncology, The, 2020, 21, 95-104.	5.1	160
53	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
54	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€¦term followâ€¦up of the randomized, openâ€¦label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	2.0	201

#	ARTICLE	IF	CITATIONS
55	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	2.0	343
56	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
57	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
58	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69
59	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	0.9	20
60	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608.	3.2	13
61	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
62	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. <i>Nature Medicine</i> , 2020, 26, 693-698.	15.2	250
63	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1606.	3.4	79
64	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
65	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	0.8	61
66	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	1.0	10
67	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
68	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
69	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162
70	Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5005-5005.	0.8	15
71	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5006-5006.	0.8	48
72	Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5009-5009.	0.8	37

#	ARTICLE	IF	CITATIONS
73	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	0.8	2
74	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. Journal of Clinical Oncology, 2020, 38, 5023-5023.	0.8	6
75	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. Journal of Clinical Oncology, 2020, 38, 5024-5024.	0.8	9
76	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. Journal of Clinical Oncology, 2020, 38, 5034-5034.	0.8	6
77	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 5062-5062.	0.8	3
78	Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.. Journal of Clinical Oncology, 2020, 38, 5080-5080.	0.8	1
79	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 609-609.	0.8	51
80	Phase I/II study of the oral HIF-2 $\hat{\pm}$ inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 611-611.	0.8	33
81	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with $\hat{\pm}$ 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 617-617.	0.8	24
82	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	0.8	3
83	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS765-TPS765.	0.8	1
84	Phase II study of the oral hypoxia-inducible factor 2 $\hat{\pm}$ (HIF-2 $\hat{\pm}$ ) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2020, 38, TPS766-TPS766.	0.8	1
85	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	0.8	3
86	FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.. Journal of Clinical Oncology, 2020, 38, 5081-5081.	0.8	1
87	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. Journal of Clinical Oncology, 2020, 38, 5077-5077.	0.8	1
88	Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.. Journal of Clinical Oncology, 2020, 38, 155-155.	0.8	1
89	Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.. Journal of Clinical Oncology, 2020, 38, 746-746.	0.8	0
90	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	0.8	1

#	ARTICLE	IF	CITATIONS
91	219â€¦Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients. , 2020, , .		0
92	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
93	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	1.1	35
94	To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. <i>Cancer</i> , 2019, 125, 3506-3513.	2.0	24
95	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Nonâ€“Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	3.4	388
96	Vascular endothelial growth factor and programmed deathâ€“1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
97	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	3.2	58
98	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€“A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	0.8	52
99	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
100	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
101	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
102	Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?. <i>Oncologist</i> , 2019, 24, 725-727.	1.9	5
103	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	3.2	179
104	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
105	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 202-210.	1.9	24
106	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6098-6106.	3.2	14
107	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
108	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , 2019, 28, 109-119.	1.5	14

#	ARTICLE	IF	CITATIONS
109	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	1.0	24
110	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 4512-4512.	0.8	30
111	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.	0.8	61
112	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 4515-4515.	0.8	3
113	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 4568-4568.	0.8	4
114	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 4569-4569.	0.8	23
115	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A. <i>Journal of Clinical Oncology</i> , 2019, 37, 4570-4570.	0.8	14
116	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 4572-4572.	0.8	1
117	Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort. <i>Journal of Clinical Oncology</i> , 2019, 37, e14160-e14160.	0.8	5
118	Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2649-TPS2649.	0.8	2
119	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4597-TPS4597.	0.8	3
120	TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 541-541.	0.8	9
121	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. <i>Journal of Clinical Oncology</i> , 2019, 37, 546-546.	0.8	42
122	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.	0.8	49
123	Results from a phase I expansion cohort of the first-in-class oral HIF-2 $\alpha$ inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. <i>Journal of Clinical Oncology</i> , 2019, 37, 558-558.	0.8	18
124	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	10
125	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	0.8	14
126	Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2019, 37, 669-669.	0.8	7



#	ARTICLE	IF	CITATIONS
127	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	0.8	11
128	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology, 2019, 9, 1483.	1.3	10
129	Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, 9550-9550.	0.8	0
130	Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 4566-4566.	0.8	0
131	Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIZ).. Journal of Clinical Oncology, 2019, 37, e14144-e14144.	0.8	1
132	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 4582-4582.	0.8	0
133	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncology, The, 2018, 19, 451-460.	5.1	228
134	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415.	5.1	305
135	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	1.6	56
136	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research, 2018, 24, 1805-1815.	3.2	45
137	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
138	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
139	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. Journal of Clinical Oncology, 2018, 36, 3529-3532.	0.8	0
140	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Research, 2018, 28, 605-610.	0.6	24
141	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	1.5	14
142	NCI 8628: A randomized phase 2 study of zivâ€flibercept and highâ€dose interleukin 2 or highâ€dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer, 2018, 124, 4332-4341.	2.0	15
143	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
144	Sequential treatment approaches inÂ the management of <i>BRAF</i> wild-type advanced melanoma: a costâ€effectiveness analysis. Immunotherapy, 2018, 10, 1241-1252.	1.0	19

#	ARTICLE	IF	CITATIONS
145	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 341-348.	0.9	5
146	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
147	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 171-179.	1.0	18
148	Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 947-957.	1.4	46
149	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
150	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4500-4500.	0.8	78
151	A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4510-4510.	0.8	8
152	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	0.8	12
153	Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4573-4573.	0.8	3
154	Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9531-9531.	0.8	1
155	Clinical and economic outcomes associated with sequential treatment in <i>BRAF</i> mutant advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9538-9538.	0.8	4
156	Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4600-TPS4600.	0.8	2
157	Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 106-106.	0.8	2
158	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	0.8	164
159	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 579-579.	0.8	10
160	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , 2018, 36, 619-619.	0.8	2
161	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS710-TPS710.	0.8	1
162	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 679-679.	0.8	0

#	ARTICLE	IF	CITATIONS
163	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. Journal of Clinical Oncology, 2018, 36, 624-624.	0.8	1
164	Integrating a paradigm shift into treatment of renal cell cancer: Effect of online CME on oncologists' knowledge and competence.. Journal of Clinical Oncology, 2018, 36, 651-651.	0.8	0
165	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	0.8	0
166	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	0.9	199
167	Developing a model for embedded palliative care in a cancer clinic. BMJ Supportive and Palliative Care, 2017, 7, bmjspcare-2016-001304.	0.8	4
168	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	0.9	209
169	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunology Research, 2017, 5, 446-454.	1.6	56
170	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	0.9	31
171	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research, 2017, 5, 17-28.	1.6	130
172	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. Cancer Medicine, 2017, 6, 1904-1914.	1.3	24
173	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. Cancer Journal (Sudbury, Mass ), 2017, 23, 63-67.	1.0	8
174	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research, 2017, 23, 1929-1936.	3.2	290
175	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2159-2168.	3.2	12
176	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
177	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 2017, 35, 3851-3858.	0.8	384
178	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology, 2017, 35, 3807-3814.	0.8	364
179	Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies. Journal of Oncology Practice, 2017, 13, e729-e737.	2.5	25
180	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. Journal of Clinical Oncology, 2017, 35, 4504-4504.	0.8	35

#	ARTICLE	IF	CITATIONS
181	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. Journal of Clinical Oncology, 2017, 35, 4505-4505.	0.8	55
182	A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2017, 35, 4506-4506.	0.8	61
183	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	0.8	1
184	A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3111-TPS3111.	0.8	5
185	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
186	Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, TPS4600-TPS4600.	0.8	2
187	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 431-431.	0.8	59
188	Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 467-467.	0.8	7
189	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8 <sup>+</sup> T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2017, 35, 477-477.	0.8	9
190	Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.. Journal of Clinical Oncology, 2017, 35, 510-510.	0.8	6
191	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	0.8	19
192	Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study.. Journal of Clinical Oncology, 2017, 35, 440-440.	0.8	3
193	Improving end-of-life care: Palliative care embedded in an outpatient oncology clinic.. Journal of Clinical Oncology, 2017, 35, 77-77.	0.8	0
194	Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.. Journal of Clinical Oncology, 2017, 35, 9528-9528.	0.8	0
195	The association of tumor infiltrating CD8 <sup>+</sup> and Foxp3 <sup>+</sup> cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	0.8	0
196	Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. Clinical Advances in Hematology and Oncology, 2017, 15, 478-488.	0.3	11
197	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer, 2016, 122, 2389-2398.	2.0	16
198	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79

#	ARTICLE	IF	CITATIONS
199	Phase 2 Study of Bevacizumab and Temezirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 304-313.e6.	0.9	11
200	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	3.2	234
201	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
202	Killer immunoglobulin-like receptor (KIR) and KIR ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1523-1532.	2.0	5
203	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	2.0	89
204	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1558-1568.	5.1	827
205	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624.	5.8	550
206	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 820-824.	2.3	36
207	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
208	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 917-927.	5.1	789
209	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , 2016, 69, 866-874.	0.9	272
210	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
211	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	0.8	517
212	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3013-3013.	0.8	4
213	Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4507-4507.	0.8	33
214	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4509-4509.	0.8	11
215	ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4511-4511.	0.8	4
216	Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4552-4552.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).. Journal of Clinical Oncology, 2016, 34, 9518-9518.	0.8	12
218	A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21006-e21006.	0.8	2
219	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	0.8	1
220	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 498-498.	0.8	21
221	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.	0.8	1
222	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2016, 34, 616-616.	0.8	0
223	Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.. Journal of Clinical Oncology, 2016, 34, e21039-e21039.	0.8	0
224	Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.. Journal of Clinical Oncology, 2016, 34, 4548-4548.	0.8	0
225	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e291-e297.	1.8	4
226	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782.	1.1	469
227	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
228	Nivolumab for the treatment of cancer. Expert Opinion on Investigational Drugs, 2015, 24, 253-260.	1.9	67
229	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinomaâ€”A Trial of the ECOGâ€”ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology, 2015, 33, 2384-2391.	0.8	75
230	Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. JAMA Oncology, 2015, 1, 433.	3.4	201
231	Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 755-763.	1.1	28
232	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	0.8	385
233	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
234	The High-Dose Aldesleukin â€”Selectâ€”Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	3.2	133

#	ARTICLE	IF	CITATIONS
235	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
236	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	13.9	4,889
237	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. Oncologist, 2015, 20, 1028-1035.	1.9	23
238	Vascular and Metabolic Implications of Novel Targeted Cancer Therapies. Journal of the American College of Cardiology, 2015, 66, 1160-1178.	1.2	157
239	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist, 2015, 20, 617-618.	1.9	9
240	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. European Journal of Cancer, 2015, 51, 2580-2586.	1.3	79
241	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 365-377.	0.9	103
242	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 1430-1437.	0.8	914
243	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. Journal of Clinical Oncology, 2015, 33, 3009-3009.	0.8	17
244	A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 3053-3053.	0.8	1
245	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. Journal of Clinical Oncology, 2015, 33, 4500-4500.	0.8	11
246	Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 4516-4516.	0.8	44
247	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
248	Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 4553-4553.	0.8	6
249	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Journal of Clinical Oncology, 2015, 33, 4559-4559.	0.8	2
250	Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2015, 33, 4566-4566.	0.8	2
251	Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.. Journal of Clinical Oncology, 2015, 33, 9004-9004.	0.8	24
252	Factors associated with worse outcome for patients with AJCC stage IIC relative to stage IIIA melanoma.. Journal of Clinical Oncology, 2015, 33, 9078-9078.	0.8	1

#	ARTICLE	IF	CITATIONS
253	CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, TPS4578-TPS4578.	0.8	24
254	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 408-408.	0.8	2
255	Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 410-410.	0.8	26
256	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
257	High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2015, 33, 423-423.	0.8	3
258	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 426-426.	0.8	7
259	Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.. Journal of Clinical Oncology, 2015, 33, 456-456.	0.8	0
260	Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry.. Journal of Clinical Oncology, 2015, 33, e20071-e20071.	0.8	0
261	Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry.. Journal of Clinical Oncology, 2015, 33, e15609-e15609.	0.8	0
262	A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS3095-TPS3095.	0.8	0
263	Impact of integrated palliative care model on end-of-life (EOL) quality metrics for patients with kidney cancer (RCC) and melanoma (M).. Journal of Clinical Oncology, 2015, 33, 137-137.	0.8	0
264	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Management and Research, 2014, 6, 279.	0.9	23
265	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
266	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. Molecular Cancer Therapeutics, 2014, 13, 3210-3218.	1.9	21
267	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
268	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2014, 312, 1744.	3.8	312
269	Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. , 2014, 2, 20.		4
270	Potential of New Therapies like Anti-PD1 in Kidney Cancer. Current Treatment Options in Oncology, 2014, 15, 137-146.	1.3	39



#	ARTICLE	IF	CITATIONS
271	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	1.6	512
272	Interferon, Interleukin-2, and Other Cytokines. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 571-583.	0.9	18
273	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	0.9	69
274	The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). <i>Journal of Personalized Medicine</i> , 2014, 4, 52-64.	1.1	12
275	Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2. , 2014, 2, P88.		0
276	Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4504-4504.	0.8	73
277	Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4505-4505.	0.8	15
278	High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4523-4523.	0.8	4
279	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4585-4585.	0.8	5
280	Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5009-5009.	0.8	41
281	Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5010-5010.	0.8	154
282	Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9001-9001.	0.8	40
283	Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9002-9002.	0.8	64
284	Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9054-9054.	0.8	3
285	A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4604-TPS4604.	0.8	2
286	Integrating palliative care into care of patients with kidney cancer and melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 56-56.	0.8	1
287	PD-L1 expression in non-clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-424.	0.8	5
288	High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 430-430.	0.8	2

#	ARTICLE	IF	CITATIONS
289	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 467-467.	0.8	13
290	Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 470-470.	0.8	3
291	A phase II biomarker trial of everolimus in patients with advanced renal cell carcinoma (08-313).. Journal of Clinical Oncology, 2014, 32, e15565-e15565.	0.8	0
292	Association between mitotic rate and lymph node metastasis in thin melanoma in the general population... Journal of Clinical Oncology, 2014, 32, e20039-e20039.	0.8	0
293	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. Journal of Clinical Oncology, 2014, 32, 4526-4526.	0.8	1
294	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 4570-4570.	0.8	0
295	Novel Immunotherapies in GU Malignancies. Current Oncology Reports, 2013, 15, 224-231.	1.8	5
296	Immune Therapy for Kidney Cancer: A Second Dawn?. Seminars in Oncology, 2013, 40, 492-498.	0.8	18
297	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2013, 36, 490-495.	1.2	25
298	<sc>PD</sc> as a potential target in cancer therapy. Cancer Medicine, 2013, 2, 662-673.	1.3	369
299	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. Journal of Clinical Oncology, 2013, 31, 3002-3002.	0.8	47
300	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 4505-4505.	0.8	56
301	Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.. Journal of Clinical Oncology, 2013, 31, 4514-4514.	0.8	29
302	Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 4570-4570.	0.8	2
303	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	0.8	8
304	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	0.8	23
305	The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2013, 31, 345-345.	0.8	14
306	Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.. Journal of Clinical Oncology, 2013, 31, 351-351.	0.8	11

#	ARTICLE	IF	CITATIONS
307	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 459-465.	5.1	995
308	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	13.9	10,727
309	Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4504-4504.	0.8	18
310	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4505-4505.	0.8	9
311	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8507-8507.	0.8	10
312	Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8508-8508.	0.8	7
313	Predicting early relapse in patients with BRAF <sup>V600E</sup> melanoma with a highly sensitive blood BRAF assay.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8516-8516.	0.8	2
314	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8569-8569.	0.8	21
315	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	0.8	3
316	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	0.8	7
317	Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4617-4617.	0.8	0
318	Genetic polymorphisms influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4635-4635.	0.8	0
319	Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4543-4543.	0.8	0
320	A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8567-8567.	0.8	0
321	Immunotherapy for Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 793-812.	0.9	23
322	Immunotherapy and Targeted Therapy Combinations in Renal Cancer. <i>Current Clinical Pharmacology</i> , 2011, 6, 207-213.	0.2	9
323	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7462-7469.	3.2	100
324	A phase 2 pilot trial of low-dose, continuous infusion, or metronomic paclitaxel and oral celecoxib in patients with metastatic melanoma. <i>Cancer</i> , 2010, 116, 1751-1756.	2.0	65

#	ARTICLE	IF	CITATIONS
325	Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data. <i>Cancer Treatment Reviews</i> , 2010, 36, 216-223.	3.4	25
326	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
327	Improving the therapeutic index of IL-2. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 862-4.	0.3	4
328	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. <i>Clinical Cancer Research</i> , 2009, 15, 7711-7718.	3.2	104
329	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	0.8	1,751
330	Analysis of PTEN and HIF-1 $\alpha$ and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon- $\gamma$ . <i>Cancer</i> , 2009, 115, 3651-3660.	2.0	87
331	The application of high-dose interleukin-2 for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2009, 26, 13-17.	1.2	24
332	Effect of temsirolimus versus interferon- $\gamma$ on outcome of patients with advanced renal cell carcinoma of different tumor histologies. <i>Medical Oncology</i> , 2009, 26, 202-209.	1.2	239
333	The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E7-E9.	0.9	40
334	Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2009, 32, 181-185.	1.2	48
335	Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 2178-2185.	0.8	238
336	Immunotherapy of Metastatic Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 320-324.	1.0	29
337	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.	13.9	3,490
338	Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4536-4541.	0.8	294
339	Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 716s-720s.	3.2	58
340	Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2-Induced Vascular Leak. <i>Clinical Cancer Research</i> , 2007, 13, 2115-2120.	3.2	43
341	Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2007, 30, 749-761.	1.2	114
342	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study. <i>Journal of Immunotherapy</i> , 2007, 30, 839-846.	1.2	6

#	ARTICLE	IF	CITATIONS
343	Immunotherapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2007, 99, 1282-1288.	1.3	22
344	What Is Standard Initial Systemic Therapy in Metastatic Renal Cell Carcinoma?. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 256-263.	0.9	2
345	Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools. <i>Current Urology Reports</i> , 2006, 7, 8-15.	1.0	4
346	Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of Response. <i>Seminars in Oncology</i> , 2006, 33, 583-587.	0.8	54
347	Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma: Update of Phase III Trials. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 114-119.	0.9	22
348	Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 488-495.	1.2	217
349	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	0.8	746
350	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3714-3721.	3.2	401
351	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. <i>Cancer Research</i> , 2005, 65, 3044-3048.	0.4	750
352	Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6342S-6346S.	3.2	133
353	Application of IL-2 and other cytokines in renal cancer. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 455-468.	1.4	81
354	Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2564-2573.	0.8	138
355	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
356	NEPHRECTOMY BEFORE INTERLEUKIN-2 THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1997, 158, 1691-1695.	0.2	150
357	Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	0